OncoMatch/Clinical Trials/NCT05859750

A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer

Is NCT05859750 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for pancreatic cancer.

Phase 2RecruitingAkesoNCT05859750Data as of May 2026

Treatment: AK104 · AK104 · Gemcitabine · Nab-Paclitaxel · Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate · Oxaliplatin + Irinotecan + 5-Fluorouracil/Leucovorin — This study is a multicenter, open-label, phase II study to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activities of AK104，a PD-1/CTLA-4 bispecific antibody, in combination with chemotherapy as first-line therapy in subjects with advanced unresectable or metastatic pancreatic ductal adenocarcinoma.

Check if I qualify

Extracted eligibility criteria

Cancer type

Pancreatic Cancer

Biomarker criteria

Excluded: BRCA1 germline mutation

Excluded: BRCA2 germline mutation

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: treatment targeting the mechanism of tumor immunity

Patients who received any prior treatments targeting the mechanism of tumor immunity [excluded].

Lab requirements

Blood counts

Kidney function

Liver function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify